Zacks Research Issues Negative Outlook for AGIO Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Research analysts at Zacks Research reduced their Q1 2025 EPS estimates for shares of Agios Pharmaceuticals in a report issued on Thursday, March 6th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings of ($1.81) per share for the quarter, down from their previous estimate of ($1.64). The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($6.85) per share. Zacks Research also issued estimates for Agios Pharmaceuticals' Q2 2025 earnings at ($1.75) EPS, Q3 2025 earnings at ($1.79) EPS, Q4 2025 earnings at ($2.02) EPS, FY2025 earnings at ($7.37) EPS, Q1 2026 earnings at ($1.76) EPS, Q2 2026 earnings at ($1.65) EPS, Q3 2026 earnings at ($1.59) EPS, Q4 2026 earnings at ($1.42) EPS and FY2026 earnings at ($6.42) EPS.

Several other research firms have also recently issued reports on AGIO. StockNews.com cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, February 14th. Royal Bank of Canada lifted their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a research note on Tuesday, December 10th. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 price target on the stock. Scotiabank raised their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, December 9th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $56.57.

Remove Ads

Agios Pharmaceuticals Trading Down 2.0 %

Shares of AGIO traded down $0.65 during mid-day trading on Monday, hitting $31.33. The company's stock had a trading volume of 214,081 shares, compared to its average volume of 681,023. The firm has a 50-day simple moving average of $33.74 and a 200 day simple moving average of $42.01. The firm has a market capitalization of $1.80 billion, a P/E ratio of 2.76 and a beta of 0.90. Agios Pharmaceuticals has a 1-year low of $27.14 and a 1-year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%.

Insider Buying and Selling

In other news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.93% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in AGIO. Summit Investment Advisors Inc. raised its position in Agios Pharmaceuticals by 7.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock worth $194,000 after purchasing an additional 394 shares in the last quarter. Federated Hermes Inc. raised its position in Agios Pharmaceuticals by 4.4% in the 4th quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock worth $450,000 after purchasing an additional 582 shares during the last quarter. KBC Group NV increased its position in Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 611 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Agios Pharmaceuticals by 6.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company's stock worth $539,000 after acquiring an additional 688 shares during the period. Finally, Alliancebernstein L.P. increased its holdings in Agios Pharmaceuticals by 1.2% in the fourth quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company's stock valued at $2,021,000 after purchasing an additional 708 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.